

Trial	Aim	Phase	Funding	Multicentre?	International?	Country	Sufficiently powered?	Follow-up (months)
Kelly 2001 <sup>48</sup>	To determine whether or not PAX + CARB offered a survival advantage over VNB + CIS	III	Public Health Service Cooperative Agreement grants (National Cancer Institute), Glaxo Wellcome Inc., Bristol-Myers Squibb	Yes	No	USA	Yes	24
Scagliotti 2002 <sup>43</sup>	To evaluate whether GEM + CIS or PAX + CARB offer any advantage over VNB + CIS	III	Eli Lilly and Company	Yes	No	Italy	Yes	24
Schiller 2002 <sup>47</sup>	To determine whether CIS + GEM, CIS + DOC or CARB + PAX are superior to CIS + PAX	Unclear	National Institutes of Health	Yes	No	USA	Yes	24
Fossella 2003 <sup>44</sup>	To investigate whether or not DOC + PLAT regimens improve survival and affect QoL compared with VNB + CIS	III	Aventis Pharma	Yes	Yes	Australia, Canada, Europe, Israel, Latin America, Lebanon, New Zealand, South Africa and the USA	Yes	24
Gebbia 2003 <sup>49</sup>	To compare VNB + CIS with GEM + CIS, and to sequential chemotherapy with GEM + IFOS followed by VNB + CIS or VNB + CIS followed by GEM + IFOS	III	NR	Yes	No	Italy	No	12
Gridelli 2003 <sup>45</sup>	To assess whether or not GEM + VNB had QoL benefits without influencing negatively on survival, compared with GEM + CIS and VNB + CIS	III	Clinical Trials Promoting Group Italy, Eli Lilly and Company, Canada; Associazione Italiana per la Ricerca sul Cancro	Yes	Yes	Canada and Italy	Yes	12
Smit 2003 <sup>46</sup>	To compare efficacy of PAX + CIS vs GEM + CIS and PAX + GEM	III	National Cancer Institute	Yes	Yes	Belgium, Egypt, Germany, Netherlands and Spain	Yes	12
Chen 2004 <sup>51</sup>	To evaluate the efficacy of weekly PAX + CIS vs VNB + CIS	II	NR	No	No	Taiwan	Yes	12

Trial	Aim	Phase	Funding	Multicentre?	International?	Country	Sufficiently powered?	Follow-up (months)
Douillard 2005 <sup>53</sup>	To evaluate DOC + CIS vs VNB + CIS and the effect of crossover to single-agent DOC or VNB at disease progression	II	Laboratoire Sanofi-aventis, France	Yes	No	France	Yes	36
Martoni 2005 <sup>54</sup>	To determine whether or not GEM + CIS offers any advantages over VNB + CIS	III	NR	Yes	No	Italy	Yes	24
Thomas 2006 <sup>58</sup>	To evaluate the efficacy and safety of GEM + CARB	II	Eli Lilly and Company, France; l'assistance publique/Hôpitaux de Marseille	Yes	No	France	Unclear	11
Chen 2007 <sup>52</sup>	To evaluate the efficacy of DOC + CIS vs VNB + CIS	II	NR	No	No	Taiwan	Yes	12
Helbekkmo 2007 <sup>55</sup>	To compare VNB + CARB and GEM + CARB for efficacy, HRQoL and toxicity	III	NR	Yes	No	Norway	Yes	12
Langer 2007 <sup>56</sup>	To evaluate PAX + CARB vs GEM + CIS	II	Public Health Service Grants, National Cancer Institute, National Institutes of Health, Department of Health and Human Services	Yes	No	USA	No	24
Ohe 2007 <sup>57</sup>	To compare efficacy and toxicity of PAX + CARB, GEM + CIS, VNB + CIS vs IRIN + CIS	III	Bristol-Myers Squibb, Japan; Eli Lilly and Company, Japan; Kyowa Hakko Kogyo Co. Ltd, Japan	Yes	No	Japan	Yes	24
Chang 2008 <sup>50</sup>	To evaluate the safety and efficacy of GEM + CIS vs VNB + CIS	Unclear	NR	No	No	Taiwan	Unclear	12
Scagliotti 2008 <sup>61</sup>	To compare the OS of PEM + CIS vs GEM + CIS	III	Eli Lilly and Company	Yes	Yes	Belgium, Brazil, Canada, Denmark, Germany, India, Italy, Korea, Netherlands Poland, Turkey and the USA	Yes	24

Trial	Aim	Phase	Funding	Multicentre?	International?	Country	Sufficiently powered?	Follow-up (months)
Gronberg 2009 <sup>62</sup>	To compare PEM + CARB vs GEM + CARB	III	Eli Lilly and Company	Yes	No	Norway	Yes	12
Mok 2009 <sup>15</sup> and Fukuoka 2011 <sup>64</sup>	To compare efficacy, safety, and AE profile of GEF vs PAX + CARB	III	AstraZeneca	Yes	Yes	Hong Kong, elsewhere in China, Indonesia, Japan, Malaysia, the Philippines, Singapore, Taiwan and Thailand	Yes	17
Tan 2009 <sup>59</sup>	To compare efficacy of day 1 i.v. VNB and day 8 oral VNB + CIS vs DOC + CIS	III	Institut de Recherche Pierre Fabre Pharmaceuticals Inc.	Yes	Yes	Australia, Austria, Belgium, Czech Republic, Finland, France, Germany, Greece, Israel, Italy, Mexico, Poland, Portugal, South Africa, Spain, Switzerland and Taiwan	No	12
Maemondo 2010 <sup>63</sup>	To compare GEF vs PAX + CARB	III	Japan Society for Promotion of Science, Japanese Foundation for the Multidisciplinary Treatment of Cancer, Tokyo Cooperative Oncology Group	Yes	No	Japan	No	24
Mitsudomi 2010 <sup>65</sup>	To compare GEF vs DOC + CIS	III	West Japan Oncology Group	Yes	No	Japan	Yes	40
Treat 2010 <sup>60</sup>	To compare GEM + CARB or GEM + PAX vs PAX + CARB	III	Eli Lilly and Company	Yes	No	USA	Yes	36

IFOS, ifosfamide; IRIN, irinotecan; NR, not reported.